ALLO Company Profile and Key Details
Allogene Therapeutics, Inc.
ALLO Stock Price Chart
Stock Price Today
Allogene Therapeutics, Inc. (ALLO) stock declined over -2.99%, trading at $1.62 on NASDAQ, down from the previous close of $1.67. The stock opened at $1.66, fluctuating between $1.61 and $1.72 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Company Information
| Employees | 232 |
| Beta | 0.84 |
| Sales or Revenue | $95.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $1.62 in the last trading session. During the trading session, ALLO stock reached the peak price of $1.72 while $1.61 was the lowest point it dropped to. The percentage change in ALLO stock occurred in the recent session was -2.99% while the dollar amount for the price change in ALLO stock was -$0.05.
The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector. Allogene Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Arun Balakumaran M.D., Ph.D.
Chief Medical Officer
Dr. Alison Moore Ph.D.
Chief Technical Officer
Dr. Eric Thomas Schmidt Ph.D.
Executive Vice President & Chief Financial Officer
Mr. Veer Bhavnagri
Gen. Counsel & Compliance Officer
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Co-Founder & Executive Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Mr. Timothy L. Moore Ph.D.
Executive Vice President & Chief Technical Officer
Ms. Barbra Sasu
Chief Scientific Officer
Mr. Stephen Cheng
Chief Information Officer
Ms. Lillian Smith
Interim Gen. Counsel & Compliance Officer
Ms. Christine Cassiano
Chief Communications Officer
Ms. Susan R. Lundeen
Chief People Officer
Ms. Diane Hagerty
Senior Vice President of Quality
Dr. Rafael G. Amado M.D.
Pres and Head of Global Oncology R&D
ALLO's closing price is 0.94% higher than its 52-week low of $1.61 where as its distance from 52-week high of $5.78 is -71.97%.
Number of ALLO employees currently stands at 232.
Official Website of ALLO is: https://www.allogene.com
ALLO could be contacted at phone 650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.
ALLO stock volume for the day was 2.91M shares. The average number of ALLO shares traded daily for last 3 months was 2.75M.
The market value of ALLO currently stands at $339.67M with its latest stock price at $1.62 and 209.67M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com